Summary
Structure-based drug design is perhaps the most elegant approach for discovering compounds exhibiting high specificity and efficacy. In reality, drug targets are very complex and this approach has had only limited utility. However, a number of recent successful drugs have in part or in whole emerged from a structure-based research approach.
Scope
This Report describes the many advances including crystallography and informatics that are behind these successes. The Report also discusses the impact these advances in structure-based drug design are likely to have on the economics of drug discovery.
Key Reasons to Buy
- Get a first-hand account of successful approaches to structure-guided drug design and the integration of classical and modern pharmacology from several descriptive case studies.
- Look inside 20+ companies utilizing structure-guided drug design for drug discovery, including their product pipelines, financial standing, partnerships & alliances, and more.
- Discover the future possibilities of structure-guided drug design from an overview of technologies on the horizon and their projected market impact.
- Gain insight into the biological systems in which drugs maneuver via an examination of hormones and receptors and how they operate.
- Obtain a complete picture of the history of drug discovery through a review of the smaller life cycles of drug development and the various life histories of particular drugs - from lead structure to market launch, from ingestion to excretion, and as a life-time brand on the market.
Company Profiles
- 7TM PHARMA
- Abbott Bioresearch Center
- Accelrys
- AnorMED
- Antigenics
- artus
- Astex Technology
- Aurigene Discovery Technologies
- Biofocus
- Bio-Xtal
- Cengent Therapeutics
- Chemical Computing Group
- Daylight Chemical Information Systems
- Evotec OAI AG
- Fluidigm Corporation
- Indivumed Center for Cancer Research
- LifeSpan BioSciences
- Migenix
- Structural GenomiX
- Sunesis Pharmaceuticals
- Synergix
- Syrrx
- Tripos
View Cart
